The adverse effects are concerning, however, the lancet trial was underpowered and had to be stopped early because there weren't enough patients [0]. That's why they say in their interpretation that even though they saw some numerical improvement in their results, larger trials are needed to evaluate statistical significance. The NIAID's trial is also a placebo-controlled randomized controlled trial and was adequately powered for reduction in recovery time, but didn't hit statistical significance at a p<.05 threshold for mortality rate.

[0]https://www.thelancet.com/journals/lancet/article/PIIS0140-6...

It had just 237 participants, so it makes sense that it didn't show significant difference.